Albuterol syrup
Pro Research Analysisby 
Searched over 200M research papers for "albuterol syrup"
Albuterol Syrup in the Treatment of Childhood Asthma
Efficacy of Albuterol Syrup in Asthma Management
Albuterol syrup has been extensively studied for its efficacy in treating asthma in children. Research indicates that albuterol syrup significantly improves pulmonary function and reduces asthma symptoms. In a study involving children aged 2 to 6 years, the combination of albuterol syrup and theophylline resulted in higher peak expiratory flow rates compared to theophylline alone (119.3 L/min vs. 83 L/min)1. Another study with children aged 3 to 6 years demonstrated that albuterol syrup significantly increased FEV1 and FEF 25%-75% over three hours, indicating improved lung function3.
Comparison with Other Formulations
When comparing albuterol syrup to other formulations, such as tablets, the syrup form has shown superior results. In a study involving children aged 6 to 14 years, albuterol syrup was found to be more effective than tablets in improving pulmonary function and reducing the need for additional medications2. The syrup formulation also had a longer duration of action, maintaining its effect for up to six hours, compared to the tablet form, which peaked at two hours and diminished after five hours2.
Safety and Side Effects
The safety profile of albuterol syrup is favorable, with minimal side effects reported. Common side effects include mild tremors and increased heart rate, but these were generally clinically unimportant3. In a study comparing albuterol syrup to metaproterenol syrup, albuterol produced fewer chronotropic effects, making it a safer option for children4. Additionally, no evidence of cardiotoxicity, such as arrhythmias or myocardial injury, was observed in children treated with albuterol syrup1.
Therapeutic Advantages Over Other Bronchodilators
Albuterol syrup has demonstrated therapeutic advantages over other bronchodilators like metaproterenol. In a study comparing the two, albuterol syrup produced greater bronchodilation and had a longer duration of action4. This makes albuterol syrup a more effective option for maintaining optimal bronchodilation over a 24-hour period.
Conclusion
Albuterol syrup is an effective and safe treatment for childhood asthma, offering significant improvements in pulmonary function and symptom control. Its superior efficacy compared to tablet formulations and other bronchodilators, along with a favorable safety profile, makes it a preferred choice for managing asthma in children.
Sources and full results
Most relevant research papers on this topic
Albuterol syrup in the treatment of asthma.
Adding albuterol to theophylline improves asthma control in children aged 2 to 6 years, reducing symptom severity and requiring less theophylline dosage without causing cardiotoxicity.
RCTOral albuterol in the treatment of childhood asthma.
Four milligrams of albuterol syrup (2 mg/5 ml) four times a day is the preferred dose for asthmatic children aged 6 to 14 years, with syrup providing longer-lasting relief and greater heart rate changes.
RCTAlbuterol syrup in the treatment of the young asthmatic child.
Albuterol syrup is effective and safe for treating young asthmatic children, reducing symptom scores and need for additional medications without significant side effects.
RCTComparison of albuterol and metaproterenol syrup in the treatment of childhood asthma.
Albuterol syrup has therapeutic advantages over metaproterenol syrup in improving pulmonary function, chronotropic effects, and frequency of dosing in children with mild to moderate asthma.
Non-RCTComparative bioavailability and pharmacokinetics of three formulations of albuterol.
The bioavailability of albuterol from tablet and solution formulations is equivalent, with rapid absorption and comparable maximum drug concentrations.
RCTTherapeutic efficacy and equivalence of tablet and syrup formulations of procaterol hydrochloride in childhood asthma.
Both tablet and syrup formulations of procaterol hydrochloride are equivalent in bronchodilating efficacy and safety for childhood asthma.
Non-RCTExtended-release albuterol in the treatment of 6- to 12-year-old asthmatic children.
Extended-release albuterol tablets (4 mg) effectively improved pulmonary function and asthmatic symptoms in children aged 6-12 years, with no serious treatment-related adverse events.
RCTAlbuterol treatment for children with asthma: a comparison of inhaled powder and aerosol.
Albuterol taken four times a day as either aerosol or dry powder is both effective and well-tolerated in children with asthma, with powder being preferred by more children.
RCTComparison of inhaled albuterol powder and aerosol in asthma.
200 micrograms of albuterol powder is as safe and effective as 180 micrograms of albuterol aerosol for treating asthma in chronic reversible obstructive airway disease patients.
RCTEfficacy of albuterol in the management of bronchiolitis.
Albuterol is as effective as oral placebo in managing bronchiolitis in infants, with past studies not considering change in infant state and using a truly inactive placebo group.
RCT
Highly Cited